glp-1 addiction Not just obesity: receptor agonists advance on GLP-1 Agonists for Addiction

10.1038/nm873

More recently, the FDA has approved select GLP-1 therapies specifically for weight loss, including: Wegovy (semaglutide) Saxenda (liraglutide) Zepbound, a GIP/GLP-1 dual-acting therapy (tirzepatide) How do they work

dpp-4_inhibitors DPP-4 Inhibitors Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)

Look for supplements that use L-Reduced Glutathione from reputable origins, contain complementary nutrients like Vitamin C and Vitamin E, and come from Clean Label Certified brands

Anti-Inflammatory Effects Another important aspect of BPC 157s mechanism of action is its anti-inflammatory properties